Lantern Pharma Inc (LTRN)

Jul 11, 2026

New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group - ACCESS Newswire

Jul 11, 2026

Jul 10, 2026

Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits

Jul 10, 2026

Jul 08, 2026

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Business Wire

Jul 08, 2026

Jul 08, 2026

Lantern Pharma’s ZetaOmics turns plain-English questions into cancer analysis - Stock Titan

Jul 08, 2026

Jul 02, 2026

LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill

Jul 02, 2026

Jun 30, 2026

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance - The National Law Review

Jun 30, 2026

Jun 26, 2026

LTRN Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 26, 2026

Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN) - TradingView

Jun 26, 2026

Jun 23, 2026

LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseConsensus Beat Rate - dars.gov.et

Jun 23, 2026

Jun 22, 2026

[EFFECT] Lantern Pharma Inc. SEC Filing - Stock Titan

Jun 22, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Institutional Confidence - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026

Jun 15, 2026

Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com

Jun 15, 2026

Jun 14, 2026

Lantern Pharma (LTRN) Faces Pressure: Shares Dip 4.67% as Technical Support at $3.69 LoomsContinuation Pattern Picks - newsline.com

Jun 14, 2026

Jun 14, 2026

LTRN Q1 2026 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Remains KeyEarnings Surprise Score - newsline.com

Jun 14, 2026

Jun 12, 2026

Lantern Pharma (LTRN) Falls 4.7% as Biotech Stock Tests Key Support ZoneDividend Growth Stocks - newsline.com

Jun 12, 2026

Jun 12, 2026

Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk - Stock Titan

Jun 12, 2026

Jun 07, 2026

Lantern Pharma (LTRN) Extends Decline: Key Support Levels in Focus After 5.28% DropRisk Parity Rebalance - newsline.com

Jun 07, 2026

Jun 02, 2026

Lantern Pharma stock jumps on lung cancer trial survival data By Investing.com - Investing.com India

Jun 02, 2026

Jun 02, 2026

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - BioSpace

Jun 02, 2026

Jun 02, 2026

Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results - GuruFocus

Jun 02, 2026

Jun 02, 2026

Lantern Pharma stock jumps on lung cancer trial survival data - Investing.com

Jun 02, 2026

Jun 02, 2026

Lantern Pharma reports trial data for lung cancer treatment - Investing.com

Jun 02, 2026

Jun 02, 2026

Lantern Pharma reports trial data for lung cancer treatment By Investing.com - Investing.com Nigeria

Jun 02, 2026

Jun 02, 2026

Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer - TradingView

Jun 02, 2026

Jun 02, 2026

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress - TipRanks

Jun 02, 2026

Jun 01, 2026

Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K - Stock Titan

Jun 01, 2026

May 31, 2026

LTRNLantern Pharma Inc Short Interest - Finviz

May 31, 2026

May 29, 2026

Lantern Pharma Edges Higher: LTRN Holds Above Support After 2.57% GainCall Spread Alert - newsline.com

May 29, 2026

May 28, 2026

Lantern Pharma Inc. (LTRN) Gains 5.74% as Shares Test Key ResistanceEase of Movement - newsline.com

May 28, 2026

May 27, 2026

LTRN Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates as Pipeline Progress ContinuesEPS Growth Report - newsline.com

May 27, 2026

May 26, 2026

Lantern Pharma Announces $9.25 Million Registered Direct Offering - geneonline.com

May 26, 2026

May 26, 2026

LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill

May 26, 2026

May 21, 2026

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com

May 21, 2026

May 19, 2026

Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK

May 19, 2026

May 19, 2026

Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com South Africa

May 19, 2026

May 19, 2026

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace

May 19, 2026

May 19, 2026

Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus

May 19, 2026